Ultragenyx Pharmaceutical Insider Sold $550K In Company Stock
Mardi Dier, CFO And Executive Vice President at Ultragenyx Pharmaceutical (NASDAQ:RARE), made a large insider sell on October 14, according to a new SEC filing.
What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Thursday showed that Dier sold 6,738 shares of Ultragenyx Pharmaceutical at prices ranging from $81.16 to $82.79. The total transaction amounted to $552,524.
Following the transaction, Dier still owns 38,762 shares of the company, worth $3,127,705.
Ultragenyx Pharmaceutical shares are trading down 0.38% at $80.69 at the time of this writing on Friday morning.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
The Importance of Insider Transactions
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down.
Transaction Codes To Focus On
Investors prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
Check Out The Full List Of Ultragenyx Pharmaceutical's Insider Trades.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
